Abstract:Abstract Introduction: There are a lot of unmet needs in patients with triple-negative breast cancer (TNBC). Fenofibrate, a PPAR-α (Peroxisome proliferator-activated receptor alpha) agonist, has been used for decades to treat hypertriglyceridaemia and mixed dyslipidaemia and recent studies showed that it may have anti-tumor effects, however, the mechanism remains unclear. Here, we assessed the ability of fenofibrate to inhibit TNBC cells proliferation and to induce apoptosis in vitro and in vivo and explored possible involved mechanisms. Methods: Utilization of cell count kit-8 method was to evaluate the anti-proliferation effect of fenofibrate. The percentage of apoptotic cells and distribution ratio of cell cycle was determined by flow cytometric analysis. The related protein levels were measured with Western Blotting methods. The inhibition of tumor growth in vivo was assessed using MDA-MB-231 xenograft mouse model. Terminal deoxytransferase-catalyzed DNA nick-end labeling assay was employed to estimate the proportion of apoptotic cells in tumor tissue sections. In order to evaluate the safety of fenofibrate, counts of leukocyte, erythrocyte, hemoglobin, platelet, aspartate transaminase,alanine transaminase and blood urea nitrogen in peripheral blood were detected. Results:Fenofibrate had anti-proliferation effects on the twelve different subtype breast cancer cell lines we studied, of which the first five most sensitive ones were all TNBC cell lines. Its induction of apoptosis of MDA-MB-231 cell lines was independent on PPAR-α status with the highest apoptosis percentage of 48.0% when compared with 4.8% in the control group. It occurred in a both time- and dose-dependent manner accompanied by up-regulation of Bad, down-regulation of Bcl-xl, Survivin and activation of caspase-3 and NF-κB pathway. Table 1:Fenofibrate induces apoptosis in MDA-MB-231 cellsFenofibrate0μM12.5μM25μM50μM100μM24H4.8%5.9%7.3%20.3%26.0%48h5.8%7.4%11.0%23.7%48.0%MDA-MB-231 cells were treated with fenofibrate at different concentrations for either 24 or 48 hours. The percentage of apoptotic cells analyzed with flow cytometry are shown in the table. Interestingly, activation of NF-κB pathway played an important role in the induction of apoptosis by fenofibtate and the apoptosis effect can be almost totally blocked by a NF-κB specific inhibitor, that is pyrrolidine dithiocarbamate(PDTC). In addition, fenofibrate led to cell cycle arrest at G1 phase accompanied by down-regulation of Cyclin D1, Cyclin-dependent kinase4(Cdk4) and up-regulation of p21, p27/Kip1.In vivo, fenofibrate significantly inhibited tumor growth in the MDA-MB-231 xengograft mouse model and induced apoptosis with a good safety profile. Table 2:The important role of activation of NF-κB pathway in apoptosis FENO 0mmFENO 50mmPDTC(-)5.9±5.0%20.5±0.9%PDTC(+)3.9±1.8%6.5±0.9%MDA-MB-231 cels were treated with Fenofibrate at different concentrations alone or with a combination of 10nM PDTC for 24 hours. The percentage of apoptotic cells analyzed with flow cytometry are shown in the table. Conclusions:Fenofibrate can induce apoptosis in TNBC in vitro and in vivo, and the mechanism is the activation of NF-κB pathway in a PPAR-α independent way, which may serve as a novel therapeutic drug for TNBC therapy. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-09-13.

Fenofibrate Inhibits Tumor Necrosis Factor-Alpha-induced Expression of CD40 and Matrix Metalloproteinase in Human Vascular Endothelial Cells.

The Protective Effect of Fenofibrate Against TNF-α-Induced CD40 Expression through SIRT1-Mediated Deacetylation of NF-κB in Endothelial Cells

Effect of Atorvastatin on MMP-9 and Tissue Factor Induced by Oxldl in Human Monocytes-Derived Macrophages

Ginsenoside Rb1 Inhibits Tumor Necrosis Factor-Alpha-Induced Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial Cells

PPAR alpha activator fenofibrate regressed left ventricular hypertrophy and increased myocardium PPAR alpha expression in spontaneously hypertensive rats]

C-reactive Protein-Induced Expression of CD40-CD40L and the Effect of Lovastatin and Fenofibrate on It in Human Vascular Endothelial Cells.

PPARα Agonist Fenofibrate Attenuates TNF-α-induced CD40 Expression in 3T3-L1 Adipocytes Via the SIRT1-dependent Signaling Pathway

Fenofibrate Improves Vascular Endothelial Function and Contractility in Diabetic Mice

Efficacy And Safety Of Fenofibrate As An Add-On In Patients With Elevated Triglyceride Despite Receiving Statin Treatment

C-Reactive Protein-Induced Expression Of Cd40-Cd40l And The Effect Of Lovastatin And Fenotibrate On It In Human Vascular Endothelial Cells

Ppar Alpha Activator Fenofibrate Modulates Angiotensin Ii-Induced Inflammatory Responses in Vascular Smooth Muscle Cells Via the Tlr4-Dependent Signaling Pathway

Modulation of LPS-mediated Inflammation by Fenofibrate Via the TRIF-dependent TLR4 Signaling Pathway in Vascular Smooth Muscle Cells.

Abstract P2-09-13: Fenofibrate Induces Apoptosis of Triple-Negative Breast Cancer Cells Via Activation of NF-kB Pathway

Abstract 5221: Plasma Levels of Tetrahydrobiopterin and Endothelial Function Were Improved by Fenofibrate Treatment in Patients with Hypertriglyceridemia

Fenofibrate Partly Prevents Oxidized-Low Density Lipoprotein Induced Immune Maturation of Human Monocyte-Derived Dendritic Cell

Fenofibrate re-couples endothelial nitric oxide synthase by restoring the level of tetrahydrobiopterin in human umbilical vein endothelial cells

Pleiotropic effects of fenofibrate therapy on rats with hypertriglycemia

Activation of PPAR Alpha by Fenofibrate Inhibits Apoptosis in Vascular Adventitial Fibroblasts Partly Through SIRT1-mediated Deacetylation of FoxO1.

Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-κB pathway

Fenofibrate Exerts Antitumor Effects in Colon Cancer via Regulation of DNMT1 and CDKN2A

Fenofibrate Ameliorates Cardiac Hypertrophy by Activation of Peroxisome Proliferator-Activated Receptor-Α Partly Via Preventing P65-Nfκb Binding to NFATc4.